Efficacy and safety of etanercept in chronic immune-mediated disease

Author： Murdaca Giuseppe   Spanò Francesca   Contatore Miriam   Guastalla Andrea   Magnani Ottavia   Puppo Francesco  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.13, Iss.5, 2014-05, pp. : 649-661

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Cetuximab: Chronic immune-mediated demyelinating polyneuropathy: case report

By  

Reactions Weekly, Vol. 1, Iss. 1332, 2010-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Immune-mediated disease pathogenesis in respiratory syncytial virus infection

By Graham B.S.   Johnson T.R.   Peebles R.S.  

Immunopharmacology, Vol. 48, Iss. 3, 2000-07 ,pp. : 237-247

Elsevier

Access to resources Recommend Favorite

Safety and Efficacy of Disease-Modifying Anti-Rheumatic Agents: Focus on the Benefits and Risks of Etanercept

By Fleischmann R.  

Drug Safety, Vol. 25, Iss. 3, 2002-01 ,pp. : 173-197

Adis International

Access to resources Recommend Favorite

Infliximab and etanercept: basis of efficacy in Crohn's disease

By  

Inpharma, Vol. 1, Iss. 1399, 2003-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Tacrolimus in the Treatment of Chronic and Refractory Late-Onset Immune-Mediated Adverse Effects Related to Silicone Injections

By Alijotas-Reig Jaume   Garcia-Gimenez Victor   Vilardell-Tarrés Miquel  

Dermatologic Surgery, Vol. 38, Iss. 1, 2012-01 ,pp. : 38-47

Elsevier

Access to resources Recommend Favorite